GSK will invest $30 billion in U.S. R&D and manufacturing, including a new biologics factory, AI upgrades, and expanded drug ...

The multi-billion, multi-year investment comes as many of GSK’s pharma peers pull away from the U.K., either suspending or ...

GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.

GSK ( NYSE: GSK) said it is planning to invest at least $30B across the U.S. in research and development and supply chain ...

Drugmaker GSK said Wednesday it would invest $30 billion in U.S. research and development and supply chain infrastructure ...

The pharmaceutical company plans to break ground on a new manufacturing facility in Upper Merion, Pennsylvania, in 2026.

GSK plans a $30 billion investment in US R&D and manufacturing, including $1.2 billion for advanced facilities and AI ...

In its statement, GSK said the $30 billion investment would include capital investments in its U.S. supply chain and more ...

GSK has announced a $30bn investment in the US over the next five years in research and development (R&D) and supply chain.

Two of the FTSE 100's largest companies are among the global drugs giants seeking to clarify how they would be affected by a ...

British pharmaceutical firm GSK has pledged to invest $30bn (£22bn) in research and manufacturing in the US over the next ...

GlaxoSmithKline has announced a $30 billion investment across US R&D and manufacturing over the next five years. Projects ...